Ardea Biosciences — Investor Presentation (December 2007)
38 slides from Ardea Biosciences's investor presentation, Dec 20, 2007
Slide 1: Safe Harbor Statement
Safe Harbor Statement Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results
Slide 2: Background
Background Acquired R&D programs from Valeant in December 2006 Assembled new, seasoned management team Rich pipeline of small-molecules focused on HIV, cancer and inflammatory diseases Fully equipped laboratories and integrated R&D organization 5
Slide 3: Investment Highlights
Investment Highlights Four NCEs in clinical trials by early 2008 Initial efficacy results in three indications during 2008 - - Phase 2a HIV results with RDEA806 - - Phase 2 gout results with RDEA806 - - Phase 1 cancer results with RDEA119 Addressing multi-billion-dollar markets - - HIV - - Gout - -
Slide 4: Ardea's Clinical-Stage Pipeline
Ardea’s Clinical-Stage Pipeline Discovery Preclinical Phase 0/1 Phase 2 Phase 3 RDEA806 NNRTI for HIV Phase 2a results 1Q08 2nd NNRTI HIV FIH PK results 1Q08 RDEA806 Gout Initiate Phase 2 1H08 RDEA119 MEKI for Cancer Initiate Phase 1 4Q07 RDEA119 MEKI for Inflammation Initiate clinical trial 1H08 2n
Slide 5: Ardea's Clinical-Stage Pipeline
Discovery Preclinical PhaseO/1 Phase2 Phase3 ) Phase 2a results 1908 RDEAS06 2°¢ NNRTI FIH PK results 1Q08 RDEAB06 Initiate Phase 2 1HO8. COSINECME 6 MEKI for Cancer Initiate Phase 1 4Q07 EOSECME MEKI for Inflammation Initiate clinical trial 1HO8 PUI tem@m = Cancer/Inflammation pul STB Ardea Bioscie
Slide 6: HIV Market Opportunity
HIV Market Opportunity Over $8 billion mature market focused on safety and convenience Three primary classes of therapies: - - 10 approved protease inhibitors (PIs) - - 11 nucleosides (NRTIs; single agents and combinations) - - Only 3 approved non-nucleosides (NNRTIs) • One not actively promoted Efa
Slide 7: RDEA806 Antiviral Activity
RDEA806 Antiviral Activity RDEA806 is Active Against the Most Common Efavirenz Mutations RDEA806 Efavirenz Virus Prevalence* EC50 EC50 FC** FC** (nM) (nM) wt 3.0 0.4 K103N 88.5% 2.3 0.76 5.9 16 K103N-P225H 32.7% 10.3 3.4 77. 212 K103N-V108I 28.8% 2.0 0.67 15. 42 K103N-K101Q 16.3% 11.6 3.8 21. 60 K10
Slide 8: Phase 1 SAD and MAD Studies
Phase 1 SAD and MAD Studies SAD (n = 74) MAD (n = 24) Single ascending doses 300 mg bid from 50 mg to 600 mg 500 mg bid Food effect 400 mg MR bid Impact of ritonavir on RDEA806 Evaluation of two formulations SAD = Single-ascending dose MAD = Multiple-ascending dose BID = Twice daily MR = Modified-re
Slide 9: Mean Trough Concentrations of RDEA806
Mean Trough Concentrations of RDEA806 Following 300 mg, 400 mg MR or 500 mg BID* 500 mg bid 400 mg MR bid 1.00 300 mg bid (µg/mL) 0.10 Conc. EC 90 = 61 EC 50 = 15 0.01 2 4 6 8 10 12 14 Day EC50 = concentration required to kill 50% of virus in vitro ; values adjusted for protein binding EC90 = concen
Slide 10: Mean Concentration-Time Profiles of RDEA806
Mean Concentration-Time Profiles of RDEA806 Following 300 mg or 500 mg BID Dosing Terminal half-life = 10-13 hr, providing 1.000 coverage for missed doses RDEA806 500 mg day 0.100 RDEA806 300 mg day 0.010 EC50 = 15 ng/mL T1/2 12.9 T1/2 = 9.9 0.001 0 10 20 30 40 50 60 70 80 Time (hr) 15
Slide 11: Adverse Events in RDEA806 MAD Study
Adverse Events in RDEA806 MAD Study Total Placebo 300 mg 500 mg 400 mg MR RDEA806 Preferred Term (N=6) bid (N=6) bid (N=6) bid* (N=6) (N=18) Number with AEs 3 4 5 5 14 Number of AEs 7 9 10 7 26 Abdominal pain 1 (17%) 2 1 3 (17%) Constipation 2 1 3 (17%) Diarrhea 1 (17%) 2 2 (11%) Dizziness 1 (17%) 1
Slide 12: MAD results consistent with decrease in cholesterol in monkey study
MAD results consistent with 13% decrease in cholesterol observed in 28-day monkey study * Efavirenz data adapted from initial 21 days of TMC278-C204 17
Slide 13: Change in Triglycerides in MAD Study
Change in Triglycerides in MAD Study *Efavirenz data adapted from initial 21 days of TMC278-C204 Triglycerides were not measured in the 300 mg bid cohort 18
Slide 14: RDEA806 Compared to the Target Product Profile
RDEA806 Compared to the Target Product Profile From preclinical and Phase 1 results to-date, RDEA806 appears to be good candidate to meet desired Target Product Profile ? Highly active against efavirenz-resistant strains ? High genetic barrier to resistance ? Better safety profile than efavirenz ã R
Slide 15: Planned Phase 2a HIV PoC Study
Planned Phase 2a HIV PoC Study RDEA806-201 Study ART-Naïve Monotherapy 1º Endpoint Change from baseline in plasma VL VL decay rate, CD4 and CD8 changes, PK/PD, safety, 2º Endpoints tolerability, genotypic and phenotypic resistance Location EU Study ART-naïve without resistance Population HIV VL 5,00
Slide 16: 2nd and 3rd Generation NNRTIs
RDEA 2nd and 3rd Generation NNRTIs Different structural classes than RDEA806 Appear to be more potent, with greater coverage of resistant strains Potentially longer half-lives Fold-Change* in Protein Adjusted EC 50 K103N ? K103N ?K103N Y188L Y181C L100I Y188L RDEA 2nd Gen NNRTI 0.8 1.3 3.5 3.2 2.2 R
Slide 17: Competitive Landscape
Competitive Landscape Other companies have also identified the opportunity to develop new NNRTIs: - - Tibotec/J&J • TMC125 — filed for FDA approval July 2007 Significant drug interactions and rash • TMC278 — Phase 3 delayed due to cardiac toxicity* - - Pfizer • UK-453,061 — Phase 2a presented at IAS
Slide 18: New Indication for RDEA806
New Indication for RDEA806 We discovered a new indication through serendipity RDEA806 produced exposure-dependent decreases in uric acid in the MAD study 24
Slide 19: Reduction in Serum Uric Acid in RDEA806 MAD Study
Reduction in Serum Uric Acid in RDEA806 MAD Study * * * * * * * * *p 0.001 Mean SUA Level (mg/dL) Baseline Day 3 Day 10/14 [1] Change P Value [2] Placebo 5.66 6.12 5.78 3.0% 300mg bid 6.19 4.50 4.15 -31.6% 0.001 500mg bid 4.94 2.94 3.06 -38.1% 0.001 400mg MR bid [3] 5.25 2.99 2.80 -47.9% 0.001 [1] P
Slide 20: Reduction in Serum Uric Acid Increases with Higher Baselines
Reduction in Serum Uric Acid Increases with Higher Baselines SUA reduction in two patients with hyperuricemia was the largest in the study; on the last day of dosing, every patient met the regulatory criteria of SUA 6 mg/dL Baseline Serum Uric Acid (mg/dL) 26
Slide 21: Why is Lowering Uric Acid Important
Why is Lowering Uric Acid Important Gout: a painful and debilitating disease - - Inflammation - - Disfiguring nodules (tophi) - - Attacks of severe pain (flares) - - Kidney damage (nephropathy) Affects 3-5 million people in the U.S. - - Most common form of inflammato ry arthritis in men over 40 - -
Slide 22: Why There Is a Need for New Drugs
Why There Is a Need for New Drugs No new drugs approved by the FDA in over 40 years 95% of treated patients receive allopurinol, but: Only 21% of patients achieved target reduction in uric acid with a standard dose in a controlled study 1 Serious adverse events in 8% 1 Rash in 2%1,2 Major allopurino
Slide 23: Competitive Landscape
Competitive Landscape Allopurinol - - 40 year old generic xanthine oxidase inhibitor, with limited efficacy and safety issues Febuxostat (TAP) - - 2nd generation xanthine oxidase inhibitor (more specific than allopurinol) - - Two approvable letters, but still in Phase 3 due to safety concerns Purica
Slide 24: Development Strategy
Development Strategy Biologic activity and safety already demonstrated in 2-week healthy volunteer study 1H08: Initiate Phase 2 dose-ranging study with RDEA806 in patients with hyperuricemia and a history of gout - - We will also monitor triglycerides and cholesterol Currently investigating active m
Slide 25: Hyperuricemia in HIV
Hyperuricemia in HIV High rates of hyperuricemia in HIV patients - - 41% in the “HAART era” HIV protease inhibitors are associated with hyperuricemia Reducing uric acid levels in HIV patients may be beneficial Nephron Physiol 2006;103:p131-p138 31
Slide 26: MEK as Anticancer Target
MEK as Anticancer Target GF Herceptin, Erbitux RTK Tarceva Proliferation Ras Angiogenesis Differentiation Raf Nexavar Apoptosis ARRY-142886 (Ph 2) PD0325901 (Ph 2?) MEK XL518 (Ph 1) c-Myc Bcl RDEA119 (Ph 1) c-Jun Elk-1 Mcl PDE4 cPLA2 ERK2 ERK2 MNK1/2 MAPKAPK1/3 33
Slide 27: RDEA119 is a Potent, Highly Specific MEKI
RDEA119 is a Potent, Highly Specific MEKI MEK1/2 Enzyme IC50 17-50 nM Cellular pERK EC50 2.5-8.7 nM* 100-fold selectivity in kinase panel of 205 enzymes at 10 µM** MEK1 & MEK2 MEK1 & MEK2 Inhibition100 RDE 100 119 PD- 3 25901 80 80 (P fizer ) 60 60 Ron 40 40 SRC % 20 20 0 0 1 1 6 6 11 11 16 16 21 21
Slide 28: Colo205 Human Colon Cancer Xenograft
Colo205 Human Colon Cancer Xenograft Lowest dose tested, 25 mg/kg, produced 7 PRs and 2 CRs out of 9 mice; 2 were tumo r-free at end of study 1200 Dosing Vehicle Period 1000 RDEA119 (mm3) 800 25mg/kg RDEA119 volume 600 50mg/kg RDEA119 400 100mg/kg Tumor 200 0 0 10 20 3 0 4 0 Days 35
Slide 29: Brain/Plasma Ratio in Rat
Brain/Plasma Ratio in Rat RDEA119 has less potent ial for CNS toxicity 5 mg/kg in rat 48 mg/subject in human PD325901 = MEK inhibitor from Pfizer 36
Slide 30: Planned Phase 1 RDEA119-101 Study in Advanced Cancer Patients
Planned Phase 1 RDEA119-101 Study in Advanced Cancer Patients Study 1º End Point Safety, tolerability, PK Pharmacodynamic (PD) measures: pERK, Ki67, Nras, Kras and 2º End Points Braf mutations; Antitumor activity by CT scan Location Von Hoff (Arizona), Weekes (UCHSC) Advanced cancer patients, all-co
Slide 31: Competitive Landscape
Competitive Landscape Pfizer - - Innovator of MEK inhibitors - - Second generation compound, PD-325901, demonstrated activity in Phase 1, but Phase 2 slowed due to toxicity Array/AstraZeneca - - December 2003 partnership - - ARRY-866/AZ-6244 in Phase 2 for melanoma, colon CA, pancreatic CA, and NSCL
Slide 32: Inhibition of Cytokines and Preclinical Results
Inhibition of Cytokines and Preclinical Results* EC50 (nM) for Cytokine Inhibition pERK RDEA119 20 152 994 45 409 100 RDEA436 15 15 37 15 36 10 Significant activity with RDEA119 observed in: - - Rat carrageenan paw edema model - - Rat adjuvant-induced arthritis model - - MDS Pharma rat IBD model - -
Slide 33: Activity of RDEA119 in TNBS-induced Colitis in Mice
Activity of RDEA119 in TNBS-induced Colitis in BALB/c Mice Macroscopic Damage Score SEM) Score (Mean ± Damage Naïve Vehicle 150 mg/kg 3 mg/kg 10 mg/kg Sulfasalazine RDEA119 RDEA119 RDEA119 administered orally for 5 days significantly reduced colonic damage * p 0.01 **p 0.001 vs. vehicle (n=10/group)
Slide 34: Efficacy of RDEA436 in Carrageenan Paw Edema Model
Efficacy of RDEA436 in Carrageenan Paw Edema Model RDEA436 has super ior efficacy to maximally effecti ve dose of 0% indomethacin 40% 38% 55% 63% 66% Compounds dosed orally, 2 hr prior to carrageenan N = 6 male SD rats/treatment group *p 0.01 Dunnett’s test compared to vehicle 41
Slide 35: Financial Position Summary
Financial Position Summary Statement of Nine Months Operations Ended (In thousands, except per share Sept. 30, 2007 data) 11.8 million common-equivalent shares outstanding Revenue $2,827 Operating expenses $20,756 Expect to end 2007 Interest and other income $1,876 with approximately NET LOSS $(16,2
Slide 36: Near-Term Anticipated Milestones
Near-Term Anticipated Milestones Date Drug Candidate Indication Event 4Q07 RDEA806 HIV Phase 2a start 1Q08 2nd Gen NNRTI HIV FIH micro-dosing 1Q08 2nd Gen MEKI Cancer/Inflam FIH micro-dosing 1Q08 RDEA806 HIV Phase 2a results (PoC) 1Q08 2nd Gen NNRTI HIV Human PK data 1Q08 2nd Gen MEKI Cancer/Inflam
Slide 37: Near-Term Anticipated Milestones
4Q07 | RDEA8O6 HIV Phase 2a start 1908 | 2°4 Gen NNRTI HIV FIH micro-dosing 1Q08 | 2"4 Gen MEKI Cancer/Inflam | FIH micro-dosing 1Q08 | RDEASO6 HIV Phase 2a results 1Q08 | 2"4 Gen NNRTI HIV Human PK data 1Q08 | 2"4 Gen MEKI Cancer/Inflam | Human PK data 2Q08 | RDEASO6 HIV Phase 2b start 2Q08 | RDEA8
Slide 38: Ardea Biosciences
Ardea (()) Biosciences Designing Solutions for Serious Diseases NASDAQ: RDEA ey Ardea )Bioscienci
Ardea Biosciences — Investor Presentation (December 2007) on 6ix